When Public Health Wins by Losing: The Counterintuitive Case for Harm Reduction

In 2023, Sweden became the first country to officially declare itself 'smoke-free,' with a daily smoking prevalence below 5%. The milestone was achieved not through nicotine abstinence—Swedes consume nicotine at European-average rates—but through snus, the moist oral tobacco product that generations of Swedish men have used instead of cigarettes. Swedish men have the lowest lung cancer mortality rate in Europe. They also have some of the highest rates of nicotine use. The paradox at the heart of Sweden's success is the paradox at the heart of the harm reduction debate: you can win the war against smoking-related death without winning the war against nicotine. In fact, you almost certainly have to.

The public health establishment has historically been allergic to this framing. The foundational assumption of tobacco control—that nicotine use itself is the problem to be solved—runs deep. It's embedded in funding priorities, career incentives, advocacy messaging, and the World Health Organization's Framework Convention on Tobacco Control. Admitting that safer nicotine products can reduce mortality without eliminating nicotine use feels like surrender. But the data is increasingly clear: the countries that have embraced harm reduction—the UK, Sweden, New Zealand, Norway—are the countries where smoking is declining fastest. The countries that have resisted it—Australia, much of the EU, the WHO's most orthodox member states—are where smoking rates have plateaued or declined more slowly. The pattern is not subtle.

The UK provides the most rigorous case study. Since Public Health England's landmark 2015 review concluding that e-cigarettes are 'at least 95% less harmful' than smoking, the UK has integrated vaping into its national smoking cessation strategy. Vaping products are available in retail settings, recommended by stop-smoking services, and even piloted in hospital emergency departments as a smoking cessation intervention for patients. The result? UK smoking rates have fallen faster than in any comparable country—from 19.9% in 2010 to 12.7% in 2023—while youth vaping rates remain below those in countries with stricter regulations. The feared 'gateway effect'—that vaping would lead nonsmoking teenagers to cigarettes—has not materialized at a population level, even as adult smokers have switched in large numbers.

The opposition to harm reduction is partly scientific, partly ideological, and partly institutional. The scientific objection—that long-term data on vaping safety is incomplete—is true but selectively applied. We don't have 30-year cohort studies on vaping because vaping hasn't existed for 30 years. We do have mechanistic data, short-term clinical data, biomarker data, and the epidemiological record of countries that have embraced harm reduction. All point in the same direction: vaping is dramatically less harmful than smoking. The standard of certainty demanded of harm reduction advocates—'prove it's safe'—is a standard that would have blocked every public health innovation in history, from seatbelts to condoms to needle exchanges.

The institutional dimension is harder to discuss but impossible to ignore. A large global apparatus of tobacco control organizations, funded by governments and philanthropies, has been built around the abstinence paradigm. Careers, budgets, and advocacy strategies have been designed around the goal of eliminating nicotine use. Accepting that millions of people will continue using nicotine—and that this outcome is consistent with massive public health gains—requires that apparatus to redefine success. It requires admitting that a policy approach the establishment has opposed for two decades was, in fact, more effective than the one it championed. Institutions are not designed to do this. They're designed to persist.

The path forward requires a reframing. The goal of tobacco control should be to minimize tobacco-related death and disease, not to maximize nicotine abstinence. These are not the same thing, and conflating them has cost lives. Every smoker who could switch to a dramatically safer nicotine product but doesn't—because the products are banned, restricted, taxed prohibitively, or misrepresented as equally dangerous—represents a failure of public health policy, not a success. The Swedish experience, the UK experience, and the accumulating evidence all point in the same direction: winning the war against nicotine is neither necessary nor sufficient for winning the war against smoking-related death. The countries that understand this are saving lives. The countries that don't are counting them.

Shareable insight: Sweden didn't eliminate nicotine. It eliminated smoking—by giving nicotine users a safer way to get it. The distinction between these two goals is the most important unresolved question in global public health.